Lite Strategy, Inc.·Healthcare
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Healthcare
Biotechnology
4
2003-12-18
0.10

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 second quarter ended December 31, 2025. During the second quarter, the Company successfully launched its strategic initiative to transform its LTC holdings into a productive reserve asset, utilizing covered call options while also implementing a $25 million stock repurchase program.

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - LiTHOS Group Ltd. (CSE: LITS) (OTC Pink: LITSF) (FSE: YU8) (WKN: A3ES4Q) ("LiTHOS" or the "Company") announces the resignation of Jennie Choboter from the board of directors of LiTHOS (the "Board") and as chief financial officer of the Company.